1
Clinical Trials associated with Next generation norovirus bivalent G1.1 and G2.4 vaccine(Vaxart) / Active, not recruitingPhase 1 A Phase 1, Single Center, Open Label, Single Dose, Dose Escalation Study to Determine the Safety and Immunogenicity of a Novel Bivalent Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Volunteers Aged ≥ 18 Years and ≤ 80 Years Old
The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
100 Clinical Results associated with Next generation norovirus bivalent G1.1 and G2.4 vaccine(Vaxart)
100 Translational Medicine associated with Next generation norovirus bivalent G1.1 and G2.4 vaccine(Vaxart)
100 Patents (Medical) associated with Next generation norovirus bivalent G1.1 and G2.4 vaccine(Vaxart)
100 Deals associated with Next generation norovirus bivalent G1.1 and G2.4 vaccine(Vaxart)